Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, August 2003, p. 2646-2648, Vol. 47, No. 8
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.8.2646-2648.2003
In Vitro Susceptibilities of Seven Leptospira Species to Traditional and Newer Antibiotics
Duane R. Hospenthal* and Clinton K. Murray
Infectious Disease Service, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas
Received 26 December 2002/
Returned for modification 27 March 2003/
Accepted 12 May 2003

ABSTRACT
Human leptospirosis is generally treated with penicillin or
doxycycline. We studied the susceptibilities of 11 serovars
(seven species) of
Leptospira to 14 antibiotics. With the exception
of chloramphenicol, all tested agents were at least as potent
as penicillin and doxycycline, with the macrolide and ketolide
drugs producing the lowest MICs (and minimal bactericidal concentrations).

TEXT
Leptospirosis is a zoonotic infection with a worldwide distribution
that is associated with both endemic disease and epidemics,
with the incidence of disease being highest in tropical climates
(
6). Infection can range in severity from clinically inapparent
to life threatening, with an epidemic case fatality rate as
high as 15% (
5). Limited studies have examined the in vitro
and in vivo effects of antibiotics against
Leptospira and leptospirosis.
Two placebo-controlled human trials of intravenous penicillin
therapy in severe or icteric disease (
4,
14) and a single trial
of oral doxycycline therapy in acute febrile illness (
7) have
found these agents to be effective in decreasing symptoms, including
days of fever, and in resolving leptospiruria. In vitro testing
is not standardized and is chiefly limited to antibiotics available
prior to 1993 (
3,
10,
13). In two of the largest published studies,
16 antimicrobial agents (penicillin G and V, ampicillin, piperacillin,
apalcillin, cephalothin, cefmetazole, moxalactam, cefoperazone,
ceftizoxime, cefotaxime, streptomycin, kanamycin, tobramycin,
amikacin, and tetracycline) were tested against five serovars
(
10) and six drugs (Q-35, norfloxacin, ofloxacin, ciprofloxacin,
tosufloxacin, and tetracycline) were tested against five serogroups
(
13). In a fatal hamster model, ampicillin, piperacillin, mezlocillin,
doxycycline, and cefotaxime were shown to prevent death (
1).
We examined the MICs and minimal bactericidal concentrations
(MBCs) of 14 antibiotics against 11
Leptospira spp. isolates
using a macrodilution broth method.
Isolates of Leptospira were obtained from the Veterinary Command Food and Drug Analysis Laboratory, Fort Sam Houston, Tex. These strains originated at the U.S. Department of Agriculture National Veterinary Services Laboratories, Ames, Iowa. Strains tested include Leptospira biflexa serovar Patoc (serogroup Semaranga, strain Patoc I), Leptospira borgpetersenii serovar Ballum (serogroup Ballum, strain S 102), L. borgpetersenii serovar Sejroe (serogroup Sejroe, strain M 84), Leptospira interrogans serovar Copenhageni (serogroup Icterohaemorrhagiae, strain M 20), L. interrogans serovar Grippotyphosa (serogroup Grippotyphosa, strain Andaman), L. interrogans serovar Icterohaemorrhagiae (serogroup Icterohaemorrhagiae, strain RGA), L. interrogans serovar Pomona (serogroup Pomona, strain Pomona), Leptospira kirschneri serovar Butembo (serogroup Autumnalis, strain Butembo), Leptospira noguchii serovar Fortbragg (serogroup Autumnalis, strain Fort Bragg), Leptospira santarosai serovar Alexi (serogroup Pyrogenes, strain HS 616), and Leptospira weilii serovar Celledoni (serogroup Celledoni, strain Celledoni). Isolates were maintained in continuous culture in Ellinghausen-McCullough-Johnson-Harris (EMJH) medium (Becton Dickinson, Sparks, Md.). Inoculum was produced from cultures grown for 7 days at 30°C, quantified by organism count using a Petroff-Hausser counting chamber under dark-field microscopy.
Amoxicillin, ampicillin, cefotaxime, ceftriaxone, chloramphenicol, doxycycline, erythromycin, penicillin G, and tetracycline were purchased from Sigma-Aldrich (St. Louis, Mo.). Other antibiotics were obtained from their manufacturers (ampicillin/sulbactam and azithromycin, Pfizer, Groton, Conn.; ciprofloxacin and moxifloxacin, Bayer, West Haven, Conn.; telithromycin, Aventis, Bridgewater, N.J.). Stock 1-mg/ml solutions were produced by using the solvents and diluents suggested in NCCLS document M7-A4 (9) or by their manufacturers. Aliquots of stock solutions were stored at -70°C until the day of use.
MIC and MBC testing was performed by using a broth macrodilution technique similar to that previously described (10). Serial twofold dilutions of antibiotics in EMJH medium resulted in final concentrations of 100 to 0.01 µg/ml (penicillin concentrations are in units per milliliter; ampicillin/sulbactam was studied in a 2:1 ratio, as found in the ampicillin/sulbactam combination Unasyn [results recorded are based on ampicillin content]). Leptospira inoculum was added to produce a final concentration of 106 organisms/ml (final volume, 2 ml), and tubes were incubated at 30°C for 7 days. The lowest concentration without visual growth was recorded as the MIC. After MIC determination, 10 µl was transferred from tubes without visible growth into 2 ml of EMJH medium and incubated for 3 weeks at 30°C. The lowest antibiotic concentration that yielded no growth by visual inspection at 3 weeks was documented as the MBC.
Results are displayed in two groups: traditional antibiotics, including doxycycline, penicillin, and other older antibiotics, in Table 1 and newer antibiotics in Table 2. MICs that suppressed 90% of the strains (MIC90s) and MBC90s are included for comparison.
Doxycycline and penicillin are currently the drugs of choice
in the treatment of human leptospirosis, based chiefly on the
fact that they are the only agents that have been studied in
randomized controlled clinical trials (
4,
7,
14). Small studies
have shown that the newer cephalosporins and other ß-lactams,
as well as fluoroquinolone antibiotics, all have good in vitro
activity against strains of
Leptospira. Animal treatment models
have documented activity of doxycycline, penicillin, ampicillin,
chlortetracycline, erythromycin, piperacillin, mezlocillin,
moxalactam, cefotaxime, and ciprofloxacin against lethal infection
with individual serovars (
1,
2).
Our study confirms prior reports of the activity of penicillin, amoxicillin, ampicillin, erythromycin, ciprofloxacin, cefotaxime, and ceftriaxone against multiple previously untested Leptospira strains (3, 8, 10, 11, 12, 13). Most previous studies of antimicrobial susceptibility have been limited to the use of only one (3, 12) or two (8) Leptospira isolates of interest. Thus, our study expands the data to include a more diverse range of strains and species. The macrolide antibiotics erythromycin and azithromycin produced excellent in vitro activity against all 11 strains studied. The recently approved agent telithromycin, first of the new ketolide antibiotics, showed the best activity of all antibiotics tested. The expanded-spectrum cephalosporins cefotaxime and ceftriaxone and the fluoroquinolones ciprofloxacin and moxifloxacin also appear to have excellent activity against leptospires. Ampicillin and amoxicillin had lower MICs than penicillin or doxycycline for almost all tested strains. Interesting, the addition of a ß-lactamase inhibitor greatly enhanced the activity of ampicillin, especially in regard to its MBC. Whether this implies additive activity of the sulbactam or production of ß-lactamase by these organisms requires further examination, as this has not been described.
MBC results revealed potentially important differences between many of the newer agents and erythromycin compared to the traditional antibiotics. As expected, the MBC90s of all drugs were higher than noted MIC90s. MBC90s of erythromycin, azithromycin, telithromycin, cefotaxime, ceftriaxone, and the combination of ampicillin with sulbactam all were lower than the MIC90s of penicillin and doxycycline. Only chloramphenicol produced a higher MBC90 than the latter two agents.
How these noted in vitro results correlate with in vivo efficacy is not clear. The next step in examining the activity of the promising agents is to test them in an animal model. In vivo activity in animal models could allow selection of agents for human treatment trials.

ACKNOWLEDGMENTS
This work was supported in part by a grant from Bayer Corporation.
The views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

FOOTNOTES
* Corresponding author. Mailing address: Brooke Army Medical Center, Infectious Disease (MCHE-MDI), 3851 Roger Brooke Dr., Fort Sam Houston, TX 78234. Phone: (210) 916-4355. Fax: (210) 916-0388. E-mail:
Duane.Hospenthal{at}amedd.army.mil.


REFERENCES
1 - Alexander, A., and R. L. Rule. 1986. Penicillins, cephalosporins, and tetracyclines in treatment of hamsters with fatal leptospirosis. Antimicrob. Agents Chemother. 30:835-839.[Abstract/Free Full Text]
2 - Alt, D. P., and C. A. Bolin. 1996. Preliminary evaluation of antimicrobial agents for treatment of Leptospira interrogans serovar pomona infection in hamsters and swine. Am. J. Vet. Res. 57:59-62.[Medline]
3 - Broughton, E. S., and L. E. Flack. 1986. The susceptibility of a strain of Leptospira interrogans serogroup icterohaemorrhagiae to amoxycillin, erythromycin, lincomycin, tetracycline, oxytetracycline and minocycline. Zentralbl. Bakteriol. Mikrobiol. Hyg. A 261:425-431.
4 - Edwards, C. N., G. D. Nicholson, T. A. Hassell, C. O. R. Everard, and J. Callender. 1988. Penicillin therapy in icteric leptospirosis. Am. J. Trop. Med. Hyg. 39:388-390.
5 - Ko, A. I., M. G. Reis, C. M. R. Dourado, W. D. Johnson, L. W. Riley, and the Salvador Leptospirosis Study Group. 1999. Urban epidemic of severe leptospirosis in Brazil. Lancet 354:820-825.[Medline]
6 - Levett, P. N. 2001. Leptospirosis. Clin. Microbiol. Rev. 14:296-326.[Abstract/Free Full Text]
7 - McClain, B. L., W. R. Ballou, S. M. Harrison, and D. L. Steinweg. 1984. Doxycycline therapy for leptospirosis. Ann. Intern. Med. 100:696-698.
8 - Murgia, R., and M. Cinco. 2001. Sensitivity of Borrelia and Leptospira to quinupristin-dalfopristin (Synercid)® in vitro. New Microbiol. 24:193-196.[Medline]
9 - NCCLS. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. NCCLS document M7-A4. NCCLS, Wayne, Pa.
10 - Oie, S., K. Hironaga, A. Koshiro, H. Konishi, and Z. Yoshii. 1983. In vitro susceptibilities of five Leptospira strains to 16 antimicrobial agents. Antimicrob. Agents Chemother. 24:905-908.[Abstract/Free Full Text]
11 - Prescott, J. 1991. Treatment of leptospirosis. Cornell Vet. 81:7-12.[Medline]
12 - Shalit, I., A. Barnea, and A. Shahar. 1989. Efficacy of ciprofloxacin against Leptospira interrogans serogroup icterohaemorrhagiae. Antimicrob. Agents Chemother. 33:788-789.[Abstract/Free Full Text]
13 - Takashima, I., M. Ngoma, and N. Hashimoto. 1993. Antimicrobial effects of a new carboxyquinolone drug, Q-35, on five serogroups of Leptospira interrogans. Antimicrob. Agents Chemother. 37:901-902.[Abstract/Free Full Text]
14 - Watt, G., L. P. Padre, M. L. Tuazon, C. Calubaquib, E. Santiago, C. P. Ranoa, and L. W. Laughlin. 1988. Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis. Lancet i:433-435.
Antimicrobial Agents and Chemotherapy, August 2003, p. 2646-2648, Vol. 47, No. 8
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.8.2646-2648.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
van de Maele, I., Claus, A., Haesebrouck, F., Daminet, S.
(2008). Leptospirosis in dogs: a review with emphasis on clinical aspects. Vet Rec.
163: 409-413
[Abstract]
[Full Text]
-
Ressner, R. A., Griffith, M. E., Beckius, M. L., Pimentel, G., Miller, R. S., Mende, K., Fraser, S. L., Galloway, R. L., Hospenthal, D. R., Murray, C. K.
(2008). Antimicrobial Susceptibilities of Geographically Diverse Clinical Human Isolates of Leptospira. Antimicrob. Agents Chemother.
52: 2750-2754
[Abstract]
[Full Text]
-
Moon, J. E., Ellis, M. C., Griffith, M. E., Hawley, J. S., Rivard, R. G., McCall, S., Hospenthal, D. R., Murray, C. K.
(2006). Efficacy of Macrolides and Telithromycin against Leptospirosis in a Hamster Model.. Antimicrob. Agents Chemother.
50: 1989-1992
[Abstract]
[Full Text]
-
MURRAY, C. K., ELLIS, M. W., HOSPENTHAL, D. R.
(2004). SUSCEPTIBILITY OF LEPTOSPIRA SEROVARS TO ANTIMALARIAL AGENTS. Am J Trop Med Hyg
71: 685-686
[Abstract]
[Full Text]
-
Murray, C. K., Hospenthal, D. R.
(2004). Determination of Susceptibilities of 26 Leptospira sp. Serovars to 24 Antimicrobial Agents by a Broth Microdilution Technique. Antimicrob. Agents Chemother.
48: 4002-4005
[Abstract]
[Full Text]
-
Murray, C. K., Hospenthal, D. R.
(2004). Broth Microdilution Susceptibility Testing for Leptospira spp.. Antimicrob. Agents Chemother.
48: 1548-1552
[Abstract]
[Full Text]